Skip to content

NSI-189

Peptidessmall molecule

Availability Clinical trials only

What it is

NSI-189 is a benzylpiperazine-aminopyridine compound developed by Neuralstem to stimulate the birth of new neurons in the hippocampus. Despite its place on peptide menus it is a small molecule, not a peptide, and sits in this lane only because it is sold alongside them. It reached phase 2 in major depression and stopped there.

Why people take it

Hippocampal neurogenesis is the most appealing idea in the whole cognitive market: not a stimulant borrowed for the afternoon, but a claim to grow tissue back. People reach for NSI-189 after depression that antidepressants did not resolve, or after a stretch of chronic stress that left memory and mood flat.

How it's delivered

Oral capsules or powder. There is no approved product, no prescribing route, and no compounding pathway; what circulates has no oversight of identity or purity, nothing like how the trial material was made.

Where the evidence stands

The definitive test was run and failed. A 12-week randomized, double-blind, placebo-controlled phase 2 study enrolled 220 adults with recurrent major depression at two dose levels and missed its primary endpoint, with no significant improvement on the Montgomery-Asberg scale at either dose. One patient-rated secondary measure reached significance at the lower dose, which does not rescue a failed primary, and the program never advanced to phase 3. No trial has tested NSI-189 in healthy cognition at all.

Estimated cost

  • No approved product and no list price
  • No clinic or telehealth listing observed on our last pass
  • Not covered by insurance

Who offers it

No clinic or telehealth provider in our research pass listed NSI-189. What circulates is unregulated product sold online, outside any oversight that would confirm what is in the capsule.

How we know

Recorded from the trial registry, the published phase 2 report, and observed online sales on our last research pass. We list no referral path to this compound and are not compensated for this entry.

Go deeper

No cognitive peptides guide yet. The Peptide Explorer entry carries the compound record, and the peptide therapy hub covers how to read a failed trial rather than the marketing that outlived it.

NSI-189 in the Peptide Explorer · Peptide Therapy for Longevity

Longevity.io is for educational purposes only and is not medical advice. We list NSI-189 so the trial record is clear, not because a compound that missed its endpoint belongs in a plan. Confirm any claim against the published trial itself.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint